Parmax Pharma control change: Shahs lift stake to 58% (2026)

Deal snapshot

Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with a group of persons acting in concert (PACs), have acquired 11,52,450 equity shares of Parmax Pharma in an off-market transaction. The acquisition was completed on August 13, 2026. Following this, the combined shareholding of the acquirers and PACs stands at 58.01% of the company’s total equity capital. The disclosure describes the development as a change in control. The change is linked to a Share Purchase Agreement (SPA) and a proposed preferential issue.

Who the acquirers are

The identified acquirers are Dhiren Chandulal Shah and Sunil Chinubhai Shah. The disclosure also names the new promoter group members as Dhiren Chandulal Shah (Acquirer 1), Sunil Chinubhai Shah (Acquirer 2), Hiren Pravin Doshi (PAC 2), and Umang Alkesh Gosalia (PAC 9). The transaction is positioned as an ownership consolidation at the company. Parmax Pharma is classified under the Healthcare sector and Pharmaceuticals & Drugs industry.

Share purchase agreement and sellers

Under the SPA, the acquirers are set to buy 11,52,450 equity shares from existing promoters Alkesh Mahasukhlal Gopani, Vipul Mahasukhlal Gopani, and Pravina Mahasukh Gopani. The transaction is explicitly described as off-market and involves the full promoter stake referenced in the disclosure. The narrative in the disclosure indicates this SPA is a key trigger behind the change in control. The reported deal commentary also mentions a price of ₹35 per share for the off-market acquisition.

Promoters exit and reclassification

The disclosure states that, upon completion of the underlying transaction, the existing promoters will cease to hold any equity shares in the company. They will also be declassified from the promoter and promoter group category. Control of the target company will shift to the acquirers and PACs, who will be identified as the new promoters. This makes the transaction more than a routine secondary share transfer, because it changes who controls the company. The cited information also states that the current promoter group has completely exited, implying promoter holding becomes 0% post-completion.

Shareholding pattern cited for March and June 2026

The cited shareholding pattern shows no quarter-on-quarter change in promoter holding across March 2026 and June 2026. Promoters are shown at 30.80% in both quarters. Retail and other investors are shown at 69.20% in both quarters. Mutual funds, foreign institutions (FII), and other domestic institutions are shown at 0% in the cited pattern. This quarter-wise snapshot provides context for how concentrated the shareholding was before the control change.

Open offer: dates, size, and price

Parmax Pharma’s mandatory open offer, led by Dhiren Chandulal Shah and Sunil Chinubhai Shah along with PACs, opens on July 30, 2026. The tendering period closes on August 12, 2026. The identified date for determining eligible shareholders is Thursday, July 16, 2026. The offer is to acquire up to 23,46,250 equity shares, representing 26.00% of the expanded voting share capital, at an offer price of ₹42.80 per equity share payable in cash. The maximum open offer consideration is cited at ₹10.04 crore, with payment of consideration scheduled for August 27, 2026.

Pre-offer vs post-offer holdings (as disclosed)

The disclosure provides a before-and-after view of holdings assuming the open offer is fully accepted. It shows the acquirers and PACs moving from 27.20% pre-offer to 94.34% post-offer of the expanded voting capital. Public shareholding is shown reducing from 41.99% to 5.66%. Existing promoters are shown moving from 30.80% to 0.00%. Separately, it is stated that the acquirer group already holds 27.20% of the current equity share capital and, through the SPA, preferential issue, and open offer, will aggregate 85,13,432 shares. The remaining public shareholders are stated to retain 5,10,599 shares, assuming full acceptance.

Preferential issue and EGM-related disclosure

Alongside the change in control, the company has been pursuing a preferential issue of equity shares and convertible warrants to identified allottees described as non-promoter group allottees. Shareholders approved issuance of 31,37,586 equity shares and 21,45,145 convertible warrants to non-promoters via preferential allotment at an EGM held on July 2, 2026. The company also issued a corrigendum to its EGM notice dated June 8, 2026. The corrigendum corrected the category of Ms. Sheetal Hiren Doshi from “Promoter” to “Promoter Group” and fixed a broken hyperlink for the Practicing Company Secretary’s certificate. In the warrant allottee table excerpt, Sheetal Hiren Doshi is shown with 21,429 warrants and total consideration of ₹7,82,159, with proposed category updated to “Promoter Group”.

Delisting intent and minimum public shareholding

The disclosure states that the acquirers and PACs have no intention to delist Parmax Pharma. It also states that if public shareholding falls below the required minimum of 25%, the acquirers undertake to take steps to comply within 12 months. With a post-offer public shareholding shown at 5.66% in the disclosed scenario, this compliance statement becomes a key part of how the transaction is framed. The numbers underline how sharply public float could reduce if the offer is fully accepted.

Company identifiers and registered office details

Parmax Pharma Ltd is identified with BSE scrip code 540359. The registered office address provided is Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Rajkot, Gujarat 360311. The listed telephone number is 02827-270534 and fax is 02827-270536. The email is info@parmaxpharma.com and the website is http://www.parmaxpharma.com.

Why the control change matters for investors

The disclosures point to a full promoter exit and promoter reclassification, which typically changes how investors track governance and control. The structure here includes an SPA, a proposed preferential issue, and a mandatory open offer, rather than a single market purchase. The post-offer holding scenario, if fully accepted, would leave a relatively small public shareholding as per the disclosed numbers. Investors typically monitor such shifts because they can affect liquidity, shareholding concentration, and compliance actions linked to minimum public float requirements. Any next steps will be tied to the stated offer timelines and the scheduled payment date of August 27, 2026.

Conclusion

Parmax Pharma’s latest disclosures describe an off-market acquisition of 11,52,450 shares by Dhiren and Sunil Shah and PACs, lifting their combined holding to 58.01% and setting up a formal change in control. The transition includes the existing promoters exiting and being declassified, while the acquirer group is set to be recognised as the new promoter group. The open offer timeline runs from July 30, 2026 to August 12, 2026, with payment scheduled for August 27, 2026, and the preferential issue process running in parallel through shareholder approvals already reported.